Emmanuel de la Mora Jimenez

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.

K. Syrigos, K. O'Byrne, Keunchil Park, 2019, The New England journal of medicine.

First-Line Nivolumab Plus Ipilimumab vs Chemotherapy in Advanced Non-Small Cell Lung Cancer With Tumor PD-L1 ≥ 1%: Patient-Reported Outcomes From CheckMate 227 Part 1.

K. Syrigos, K. O'Byrne, T. Ciuleanu, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.